Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Mukherjee

Showing results (351-360 of 413) with videos related to

Pageof 42
Sort By:
Current Oncology (Toronto, Ont.)|September 25, 2019
An evaluation of the safety of continuing trastuzumab despite overt left ventricular dysfunctionC C Barron, M M Alhussein, U Kaur, et al.
Investigational New Drugs|March 2, 2010
A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II ConsortiumSrikala S Sridhar, Eric Winquist, Andrea Eisen, et al.
Heart (British Cardiac Society)|October 19, 2005
Impact of pre-diabetic state on clinical outcomes in patients with acute coronary syndromeR Otten, E Kline-Rogers, D J Meier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2011
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06cFred Saad, Sebastien Hotte, Scott North, et al.
NPJ Breast Cancer|March 6, 2020
The LISA randomized trial of a weight loss intervention in postmenopausal breast cancerPamela J Goodwin, Roanne J Segal, Michael Vallis, et al.
Scientific Reports|July 17, 2023
Microbe-metabolite interaction networks, antibiotic resistance, and in vitro reconstitution of the penile prosthesis biofilm support a paradigm shift from infection to colonizationGlenn T Werneburg, Scott D Lundy, Daniel Hettel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2022
Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU)Jonathan E Rosenberg, Se Hoon Park, Vadim Kozlov, et al.
Scientific Reports|July 18, 2025
Implementing exercise and self-management for women with breast cancer during treatment: results of the NEXT-BRCA randomized controlled trialJenna Smith-Turchyn, Derek W Stouth, Joshua A J Keogh, et al.
Oncogenesis|May 23, 2017
AKT is indispensable for coordinating Par-4/JNK cross talk in p21 downmodulation during ER stressR U Rasool, D Nayak, S Chakraborty, et al.
Neurourology and Urodynamics|May 29, 2024
Sacral neuromodulation device biofilm differs in the absence and presence of infection, harbors antibiotic resistance genes, and is reproducible in vitroGlenn T Werneburg, Daniel Hettel, Ava Adler, et al.
Pageof 42

Showing results (351-360 of 413) with videos related to

Sort By:
Pageof 42
Current Oncology (Toronto, Ont.)|September 25, 2019
An evaluation of the safety of continuing trastuzumab despite overt left ventricular dysfunctionC C Barron, M M Alhussein, U Kaur, et al.
Investigational New Drugs|March 2, 2010
A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II ConsortiumSrikala S Sridhar, Eric Winquist, Andrea Eisen, et al.
Heart (British Cardiac Society)|October 19, 2005
Impact of pre-diabetic state on clinical outcomes in patients with acute coronary syndromeR Otten, E Kline-Rogers, D J Meier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2011
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06cFred Saad, Sebastien Hotte, Scott North, et al.
NPJ Breast Cancer|March 6, 2020
The LISA randomized trial of a weight loss intervention in postmenopausal breast cancerPamela J Goodwin, Roanne J Segal, Michael Vallis, et al.
Scientific Reports|July 17, 2023
Microbe-metabolite interaction networks, antibiotic resistance, and in vitro reconstitution of the penile prosthesis biofilm support a paradigm shift from infection to colonizationGlenn T Werneburg, Scott D Lundy, Daniel Hettel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2022
Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU)Jonathan E Rosenberg, Se Hoon Park, Vadim Kozlov, et al.
Scientific Reports|July 18, 2025
Implementing exercise and self-management for women with breast cancer during treatment: results of the NEXT-BRCA randomized controlled trialJenna Smith-Turchyn, Derek W Stouth, Joshua A J Keogh, et al.
Oncogenesis|May 23, 2017
AKT is indispensable for coordinating Par-4/JNK cross talk in p21 downmodulation during ER stressR U Rasool, D Nayak, S Chakraborty, et al.
Neurourology and Urodynamics|May 29, 2024
Sacral neuromodulation device biofilm differs in the absence and presence of infection, harbors antibiotic resistance genes, and is reproducible in vitroGlenn T Werneburg, Daniel Hettel, Ava Adler, et al.
Pageof 42